medRxiv PreprintsInternational20 November 2026
Evaluation of Semaphorin 3G (SEMA3G) as a biofluid biomarker of cerebral amyloid angiopathy: evidence from neurodegenerative disease and memory clinic cohorts
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Introduction: Cerebral amyloid angiopathy (CAA) is characterised by amyloid-beta (A{beta}) deposition in cerebral vessels, and frequently co-occurs with Alzheimer's disease (AD). Diagnosis based on MRI-based Boston criteria is not definitive, and CAA biofluid biomarkers are needed. Semaphorin 3G (SEMA3G) was recently shown to be selectively enriched in CAA-affected vessels, and correlated with CAA severity. We therefore evaluated SEMA3G as a biofluid biomarker of CAA. Methods: SEMA3G profiles were examined across diagnoses in the Global Neurodegeneration Proteomics Consortium dataset (GNPC) in
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.